UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE
13D
(Rule
13d-101)
INFORMATION TO
BE INCLUDED IN STATEMENTS FILED PURSUANT
TO
§ 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO
§ 240.13d-2(a)
(Amendment
No. )1
AXIM
Biotechnologies, Inc.
(Name of Issuer)
Common
Stock, par value $.0001
(Title of Class of Securities)
05463J
107
(CUSIP Number)
John
W. Huemoeller II
6191
Cornerstone Court, E., Suite 114
San
Diego, CA 92121
(858)923-4422
(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)
February 20, 2019
(Date of Event which Requires Filing of this Statement)
If the
filing person has previously filed a statement on Schedule 13G to
report the acquisition that is the subject of this Schedule 13D,
and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f)
or 240.13d-1(g), check the following box. ¨
Note: Schedules filed in paper format shall include a signed
original and five copies of the schedule, including all exhibits.
See §240.13d-7 for other parties to whom copies are to be sent.
________________________________________
1* The remainder of this cover page shall be filled out
for a reporting person's initial filing on this form with respect
to the subject class of securities, and for any subsequent
amendment containing information which would alter disclosures
provided in a prior cover page.
The
information required on the remainder of this cover page shall not
be deemed to be "filed" for the purpose of Section 18 of the
Securities Exchange Act of 1934 ("Act") or otherwise subject to the
liabilities of that section of the Act but shall be subject to all
other provisions of the Act (however, see the Notes).
|
|
|
|
|
CUSIP No. 05463J
107
|
|
13D
|
|
Page 2
of 4 Pages
|
|
|
|
|
|
1.
|
|
NAMES OF REPORTING
PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES
ONLY)
Juniper & Ivy Corporation (EIN-84-2490117)
|
|
|
2.
|
|
CHECK THE APPROPRIATE
BOX IF A MEMBER OF A GROUP
(see instructions)
(a) ¨
(b) ¨
|
|
|
3.
|
|
SEC USE ONLY
|
|
|
4.
|
|
SOURCE OF FUNDS (see
instructions)
OO
|
|
|
5.
|
|
CHECK BOX IF
DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d)
or 2(e) ¨
|
|
|
6.
|
|
CITIZENSHIP OR PLACE
OF ORGANIZATION
USA
|
|
|
|
|
|
|
|
NUMBER
OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
|
|
7.
|
|
SOLE VOTING POWER
500,000
|
|
8.
|
|
SHARED VOTING
POWER
0
|
|
9.
|
|
SOLE DISPOSITIVE
POWER
500,000
|
|
10.
|
|
SHARED DISPOSITIVE
POWER
0
|
|
|
|
|
|
11.
|
|
AGGREGATE AMOUNT
BENEFICIALLY OWNED BY EACH REPORTING PERSON
500,000
|
|
|
12.
|
|
CHECK
BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
(see instructions) ¨
|
|
|
13.
|
|
PERCENT OF CLASS
REPRESENTED BY AMOUNT IN ROW (11)
100%
|
|
|
14.
|
|
TYPE OF REPORTING
PERSON (see instructions)
CO
|
|
|
CUSIP No. 05463J
107
|
|
13D
|
|
Page 3
of 4 Pages
|
Item
1. Security and Issuer.
This Schedule 13D relates to the Series C Preferred stock,
par value $.0001 per share, (the “Shares”) of AXIM Biotechnologies,
Inc., a Nevada corporation (the “Company” or the “Issuer”).
The principal executive offices of the Company are 6191
Cornerstone Court, E., Suite 114, San Diego, CA 92121.
Item
2. Identity and Background.
(a) This statement is filed by Juniper & Ivy Corporation
(the “Reporting Person”) a Nevada corporation.
(b) The principal business of Reporting Person is a holding
company.
(c) The Reporting Person’s principal address is 5201 Memorial
Drive #616, Houston, TX 77007.
(d) The Reporting Person has not been convicted in a criminal
proceeding (excluding traffic violations or similar misdemeanors)
during the last five years.
(e) The Reporting Person has not been a party to a civil proceeding
of a judicial or administrative body resulting in a judgment,
decree or final order enjoining future violations of, or
prohibiting or mandating activities subject to, federal or state
securities laws, or finding any violation with respect to such
laws.
Item
3. Source or Amount of Funds or Other
Consideration.
Reporting
Person purchased the Shares with private funds at a purchase price
of One Dollar ($1.00) per share. Payment was made with a
$65,000 cash payment and a $435,000 face value promissory
note.
Item
4. Purpose of Transaction.
The Reporting Person acquired the Shares, and holds the Shares, for
investment purposes. Depending on the factors discussed herein, the
Reporting Person may, from time to time, acquire additional shares
of common stock and/or retain and/or sell all or a portion of the
Shares held by the Reporting Person in the open market or in
privately negotiated transactions, and/or may distribute the Shares
held by the Reporting Person to other entities. Any actions the
Reporting Person might undertake will be dependent upon the
Reporting Person’s review of numerous factors, including, among
other things, the price levels of the Issuer’s common stock,
general market and economic conditions, ongoing evaluation of the
Issuer’s business, financial condition, operations and prospects,
the relative attractiveness of alternative business and investment
opportunities, investor’s need for liquidity, and other future
developments. Any future acquisitions of the Issuer’s securities
will be subject to the Company’s policies, including its insider
trading policy, as applicable. Except as set forth above, the
Reporting Person has no present plans or intentions which would
result in or relate to any of the transactions described herein
this Item 4.
Item 5. Interest in Securities of the Issuer.
(a)
The aggregate number of shares of Series C Preferred Stock to
which this Schedule 13D relates is 500,000 shares. The shares
represent 100% of the Series C Preferred Stock issued and
outstanding.
(b)
Reporting Person has sole voting and dispositive power over
the shares of common stock in which Reporting Person owns.
(c) See
Item 3, above.
(d) Not
Applicable.
(e) Not
Applicable.
Item
6. Contracts, Arrangements, Understandings or
Relationships with Respect to Securities of the Issuer.
None
Item
7. Material to Be Filed as Exhibits.
None
|
|
|
|
|
CUSIP No. 05463J
107
|
|
13D
|
|
Page 4
of 4 Pages
|
SIGNATURE
After reasonable inquiry and to the best of my knowledge and
belief, I certify that the information set forth in this statement
is true, complete and correct.
|
/s/
John W. Huemoeller II
|
|
John
W. Huemoeller, President
|